MTOR and central nervous system cancer: Guillard and colleagues profiled gene expression following treatment of human glioma cells with the class I PI3K/mTOR inhibitor PI-103 (18) and detected  altered expression of genes encoding regulators of the cell cycle and cholesterol metabolism, together with genes modulated by insulin or IGF1 signalling, rapamycin treatment or nutrient starvation [111].